PJP is trading at $137.83, up 4.74%, in pre-market; no clear catalyst for the rise has been identified.

  • No clear company-specific announcement or news explaining PJP’s November 5 pre-market rise was found.
  • Recent coverage notes the ETF holds U.S. pharmaceutical companies but identifies no new catalyst.
  • Supplied market context is mixed and does not establish a broad-market explanation.